About: Naltalimide

An Entity of Type: book, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Naltalimide (INN) (code name TRK-130, formerly TAK 363) is a novel, centrally-acting opioid drug which is under development by Takeda and Toray for the treatment of overactive bladder/urinary incontinence. It acts as a potent and selective partial agonist of the μ-opioid receptor (Ki = 0.268 nM, EC50 = 2.39 nM, Emax = 66.1%) over the δ-opioid (Ki = 121 nM, EC50 = 26.1 nM, Emax = 71.0%) and κ-opioid receptors (Ki = 8.97 nM, EC50 = 9.51 nM, Emax = 62.6%). Notably, naltalimide somehow appears to lack certain undesirable side effects such as constipation seen with other μ-opioid receptor agonists such as morphine. It enhances bladder storage via suppression of the afferent limb of the micturition reflex pathway.

thumbnail
Property Value
dbo:abstract
  • Naltalimide (INN) (code name TRK-130, formerly TAK 363) is a novel, centrally-acting opioid drug which is under development by Takeda and Toray for the treatment of overactive bladder/urinary incontinence. It acts as a potent and selective partial agonist of the μ-opioid receptor (Ki = 0.268 nM, EC50 = 2.39 nM, Emax = 66.1%) over the δ-opioid (Ki = 121 nM, EC50 = 26.1 nM, Emax = 71.0%) and κ-opioid receptors (Ki = 8.97 nM, EC50 = 9.51 nM, Emax = 62.6%). Notably, naltalimide somehow appears to lack certain undesirable side effects such as constipation seen with other μ-opioid receptor agonists such as morphine. It enhances bladder storage via suppression of the afferent limb of the micturition reflex pathway. (en)
dbo:casNumber
  • 160359-68-2
dbo:fdaUniiCode
  • PUO0LMS4NX
dbo:pubchem
  • 16066809
dbo:thumbnail
dbo:wikiPageID
  • 44928319 (xsd:integer)
dbo:wikiPageLength
  • 3877 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1090162142 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • None (en)
dbp:c
  • 28 (xsd:integer)
dbp:casNumber
  • 160359 (xsd:integer)
dbp:chemspiderid
  • 17226389 (xsd:integer)
dbp:h
  • 28 (xsd:integer)
dbp:iupacName
  • 2 (xsd:integer)
dbp:n
  • 2 (xsd:integer)
dbp:o
  • 5 (xsd:integer)
dbp:pubchem
  • 16066809 (xsd:integer)
dbp:smiles
  • c1ccc2cCN[C@@H]3CC[C@]4O (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • DHAITNWJDOSRBU-IBHWKQIPSA-N (en)
dbp:unii
  • PUO0LMS4NX (en)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Naltalimide (INN) (code name TRK-130, formerly TAK 363) is a novel, centrally-acting opioid drug which is under development by Takeda and Toray for the treatment of overactive bladder/urinary incontinence. It acts as a potent and selective partial agonist of the μ-opioid receptor (Ki = 0.268 nM, EC50 = 2.39 nM, Emax = 66.1%) over the δ-opioid (Ki = 121 nM, EC50 = 26.1 nM, Emax = 71.0%) and κ-opioid receptors (Ki = 8.97 nM, EC50 = 9.51 nM, Emax = 62.6%). Notably, naltalimide somehow appears to lack certain undesirable side effects such as constipation seen with other μ-opioid receptor agonists such as morphine. It enhances bladder storage via suppression of the afferent limb of the micturition reflex pathway. (en)
rdfs:label
  • Naltalimide (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License